Novartis is responding to COVID-19 with the safety of our associates and patients we serve as our main concern. We continue to contribute to global research efforts, support local communities and ensure stable supply and price of essential medicines. This US information center provides updates, guidance and other resources.
Information update about the Novartis CAN-COVID trial
The CAN-COVID clinical trial has been one of the ways Novartis is drawing on its global resources and scientific expertise in response to the COVID-19 pandemic.
Life Science Companies and the Bill & Melinda Gates Foundation: Joint Communique
Commitments to expanded global access for COVID-19 diagnostics, therapeutics, and vaccines.
Novartis US response to COVID-19
Since the first reports of the COVID-19 outbreak globally and in the US, our primary concern at Novartis has and continues to be the health and safety of our associates and patients.
Novartis US COVID-19 Initiatives
We recognize the profound impact that COVID-19 has had on patients and physicians in the US, and have worked to create solutions in a time of uncertainty and change.
Coronavirus disease (COVID-19) Global updates
As Novartis continues to closely monitor the coronavirus situation, our primary concern is the health and safety of our associates and patients globally.
Novartis COVID-19 Global Information Center
Novartis is responding to the coronavirus disease (COVID-19) outbreak. The information center provides a central hub for news, guidance and resources.